Published May 22, 2023

Casey Mulligan on Vaccines, the Pandemic, and the FDA

Economist Casey Mulligan delves into the vaccine development challenges during COVID-19, critiques FDA regulatory impacts on drug approvals, and advocates for a balanced approach to pandemic trade-offs, highlighting the vital roles of innovation, partnerships, and voluntary cooperation in public health.

Episode Highlights

Topics covered

Vaccine Development
01
FDA Regulation Impact
02
Pandemic Trade-offs
03

Casey Mulligan on Vaccines, the Pandemic, and the FDA

Topics covered

Popular Clips

FDA Policy Battles

The Costly Consequences

The Power of Freedom

Examining Opportunity Costs

The Power of Packaging

The Opioid Crisis

Geriatocracy and the Value of Being Together

Trade-offs, Vaccines

Operation Warp Speed

Maximizing Life's Rewards

Vaccine Marketing Lessons

Regulatory Barriers and Vaccine Innovation

COVID Origins and Presidential Response

FDA's Impact

Episode Highlights

Vaccine Development

FDA Regulation Impact

Pandemic Trade-offs

Casey Mulligan on Vaccines, the Pandemic, and the FDA

Topics covered

Popular Clips

Episode Highlights

Vaccine DevelopmentThe conversation with Casey Mulligan explores the innovative approaches and distribution challenges faced during the COVID-19 pandemic. He discusses the critical role of partnerships and regulatory hurdles in vaccine development and distribution.

Vaccine Development

FDA Regulation Impact

Pandemic Trade-offsCasey Mulligan examines the impact of school closures, social isolation, and economic freedom during the pandemic. He argues for a balanced approach to public health decisions, emphasizing the importance of human interaction and the power of voluntary cooperation.

Pandemic Trade-offs